Take­da CEO Christophe We­ber fi­nal­ly clos­es on his $62B deal to buy Shire — now he has to con­vince share­hold­ers and slash jobs

Take­da CEO Christophe We­ber has fi­nal­ly closed his $62 bil­lion deal to buy out Shire. Now comes an even hard­er part.

The two com­pa­nies an­nounced the pact overnight, with Shire’s board ac­cept­ing We­ber’s of­fer of £49 a share, which val­ues the com­pa­ny at £46 bil­lion. Now he’ll have to sell it to share­hold­ers — which is not a giv­en af­ter Take­da saw its mar­ket cap plunge more than 20% dur­ing the talks.

Flem­ming Orn­skov

If he gets past that hur­dle We­ber will then need to knit to­geth­er a new top 10 — by sales — glob­al phar­ma com­pa­ny while carv­ing out $1.4 bil­lion in cost syn­er­gies. About $600 mil­lion will come out of two R&D or­ga­ni­za­tions that have al­ready been through sev­er­al cy­cles of re­struc­tur­ing. Slight­ly more than half will come from sales and ad­min­is­tra­tion.

That means job cuts.

Drill down in­to the fine print of the deal, and you’ll find that the top ex­ecs at Take­da will ax 6% to 7% of the com­bined work­force. About a third of that will come out of R&D, with the bulk of the cuts be­ing made to sales and ad­min­is­tra­tion. With about 30,000 staffers at Take­da and 22,000 at Shire, a 7% cut would cost the jobs of about 3,640 peo­ple.

The new Take­da that emerges will be based in Tokyo with ex­pand­ed op­er­a­tions in the Cam­bridge/Boston area, which will con­tain the bulk of its R&D group. The Japan­ese com­pa­ny says it will then start a re­view of fa­cil­i­ties, to see which Shire labs and of­fices will stay and which will go. Man­u­fac­tur­ing ops will al­so be in­te­grat­ed.

The new com­pa­ny will be left with re­gion­al groups in Japan, Sin­ga­pore, Switzer­land and the US. But Shire’s of­fi­cial head­quar­ters in Dublin, which will no longer be need­ed, may well face the ax.

The merg­er of these two com­pa­nies, with the small­er Take­da cap­tur­ing the larg­er prey, gives We­ber the glob­al trans­for­ma­tion he was asked to de­liv­er. But it al­so has raised se­ri­ous ques­tions about the longterm vi­a­bil­i­ty of the Shire or­ga­ni­za­tion he’s buy­ing, which has an ag­ing fran­chise in AD­HD and a ma­jor new threat to its he­mo­phil­ia op­er­a­tions from Roche’s Hem­li­bra. 

Un­der CEO Flem­ming Orn­skov, Shire bought out Bax­al­ta for $32 bil­lion, and has been com­bin­ing its drugs in­to a pipeline heav­i­ly fo­cused on rare dis­eases, giv­ing Take­da what it likes to call a com­ple­men­tary or­ga­ni­za­tion to its own con­cen­tra­tion on on­col­o­gy, gas­troen­terol­o­gy and cen­tral ner­vous sys­tem ther­a­peu­tic ar­eas plus vac­cines.

Thomas Dit­trich

Take­da al­so set aside $9.1 mil­lion for re­ten­tion bonus­es to keep the ser­vices of some key per­son­nel, which will dou­ble the pay and bonus­es due to CEO Orn­skov and CFO Thomas Dit­trich.

JP Mor­gan Chase Bank, Sum­it­o­mo Mit­sui Bank­ing Cor­po­ra­tion and MUFG Bank have put to­geth­er a $31 bil­lion bridge loan to com­plete the cash por­tion of the deal, which will lat­er be re­struc­tured in­to a longterm loan as Take­da tries to con­vince the cred­it rat­ing groups to show some mer­cy on its rat­ings.


Im­age: Christophe We­ber. GET­TY IM­AGES

Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy that could tackle solid tumors.

Its founders have helped hone a new approach that would pack in multiple neoantigen targets to create a personalized TCR treatment that would not just make the leap from blood to solid tumors, but do it with durability. And they managed to make their way rapidly to the clinic, unveiling their first Phase I program for advanced tumors just last May.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Tim Van Hauwermeiren, argenx CEO

Ar­genx pur­chas­es $100M+ FDA pri­or­i­ty re­view vouch­er from blue­bird bio

Argenx’s Vyvgart is due for a speedy review at the FDA, thanks to a $102 million priority review voucher (PRV).

The Netherland-based biotech picked up the PRV from bluebird bio, the companies announced on Wednesday. PRVs shorten a drug’s FDA review period from 10 months to 6 months, though they often sell on the open market for around $100 million each.

Argenx plans on using the express ticket on efgartigimod, its neonatal Fc receptor (FcRn) blocker marketed as Vyvgart for adults with generalized myasthenia gravis (gMG). While Vyvgart won its first approval last December for the chronic neuromuscular disease — which is characterized by difficulties with facial expression, speech, swallowing and breathing — CEO Tim Van Hauwermeiren said in a news release that he plans to “be active in fifteen disease targets by 2025.”

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Lil­ly's Covid-19 mAb no longer au­tho­rized due to Omi­cron sub­vari­ants, FDA says

The FDA on Wednesday announced that Eli Lilly’s Covid-19 drug bebtelovimab is no longer authorized to treat Covid-19 because of the rising numbers of two new subvariants that the drug does not work against.

The Centers for Disease Control and Prevention last week published new estimates that the combined proportion of Covid-19 cases caused by the Omicron subvariants BQ.1 and BQ.1.1 are greater than 57% nationally, and already above 50% in all individual regions but one.

Uğur Şahin, BioNTech CEO (ddp images/Sipa USA/Sipa via AP Images)

BioN­Tech bets on dif­fi­cult STING field via small mol­e­cule pact with a Pol­ish biotech

BioNTech is beefing up its relatively thin small molecule pipeline by adding weight to a clinically difficult corner of oncology R&D: STING agonists. To do so, BioNTech is teaming up with a 15-year-old Polish biotech and doling out €40 million, about $41.5 million, to start.

The deal is broken into two parts: First, BioNTech obtains an exclusive global license to develop and market Ryvu Therapeutics’ STING agonist portfolio as small molecules, whether alone or in combination with other agents.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Tim Walbert, Horizon Therapeutics CEO (via YouTube)

Hori­zon Ther­a­peu­tics in takeover talks with Am­gen, J&J, Sanofi as po­ten­tial buy­ers

Amgen, J&J’s Janssen and Sanofi are all in talks to acquire Horizon Therapeutics, the rare disease biotech disclosed late Tuesday.

Horizon confirmed “highly preliminary discussions” with those companies regarding a potential buyout offer after the Wall Street Journal reported takeover interest.

Although the company — which commands a market cap of close to $18 billion — emphasized that “there can be no certainty that any offer will be made for the Company,” shares $HZNP still surged 31% in after-hours trading to near $103, bringing it to the point where it started the year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi and DN­Di aim to elim­i­nate sleep­ing sick­ness in Africa with promis­ing Ph II/III re­sults for new drug

The Drugs for Neglected Diseases initiative (DNDi) and Sanofi today said that their potential sleeping sickness treatment saw success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole.

The potentially transformative treatment for sleeping sickness would mainly be targeted at African countries, according to data published today in The Lancet Infectious Diseases medical journal. The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo (DRC) and Guinea, with the authors noting:

Illustration: Assistant Editor Kathy Wong for Endpoints News

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

Pharma advertisers on Twitter are done — at least for now. Ad spending among the previous top spenders flattened even further last week, according to the latest data from ad tracker Pathmatics, amid ongoing turmoil after billionaire boss Elon Musk’s takeover now one month ago.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer. GSK spending for the full week through Sunday was minimal at just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier upping its spending to $499,000 last week from $480,000 the previous week. Bayer’s spending also marks a big increase from a month ago and before the Musk takeover, when it spent $16,000 per week.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

After 24 years without confirming clinical benefit, the FDA announced Tuesday morning that Viatris (formed via Mylan and Pfizer’s Upjohn) has decided to withdraw a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said conducting a confirmatory study was not feasible.

Sulfamylon first won FDA’s accelerated nod in 1998 as a topical burn treatment, with the FDA noting that last December, Mylan told the agency that it wasn’t running the trial.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.